FDA Warns of Barcode Display Errors on Nova Biomedical Hospital Glucose Meters
The Food and Drug Administration warned that Nova Biomedical has updated operating instructions for its StatStrip Glucose Hospital Meter Gen 2.0 due to a software display problem. The FDA classified this as its most serious recall category because the defect may cause serious injury or death. When hospital staff scan a patient barcode, older information can remain on the meter screen. If staff accept the old details, a blood glucose test result gets attached to the wrong patient record. That error can lead clinicians to give unnecessary insulin or delay care. Nova Biomedical reported one serious injury and no deaths connected to the problem as of October 5, 2026. Hospitals with alternative glucose meters should stop using the affected Gen 2.0 units immediately. Facilities without backup meters must follow manual safety steps while waiting for a software update that Nova Biomedical plans to release in November 2026.
What was announced
The FDA updated a safety communication on October 30, 2026, about a Class I recall for the Nova Biomedical StatStrip Glucose Hospital Meter System Gen 2.0. A Class I recall is the agency's label for situations where an issue with a medical device can cause severe harm or death. The recall covers model numbers 63685 and 66739.
Nova Biomedical sent an initial letter to customers on July 31, 2026, followed by a revised notice on October 5. The manufacturer reported that prior patient or quality control barcode data can stay visible on the screen during a scan. If an operator accepts that stale data, the meter records the blood sugar test under the wrong person's medical file.
Shipments of all new Gen 2.0 units are currently on hold while Nova Biomedical validates a software patch. The company stated that it plans to release this software update in November 2026. Until then, hospitals with alternative meters should stop using the Gen 2.0 devices. Hospitals keeping them in service must set the meters to log operators off after every test, verify patient details twice during testing, and flag any misassigned records in their electronic systems.
What it means
The issue does not change how accurately the meter analyzes blood sugar samples. Instead, it creates an identification mismatch inside clinical records.
When a glucose reading attaches to the wrong patient, healthcare workers can act on bad data. A clinician might give insulin to someone who does not need it, or fail to treat someone experiencing low blood sugar. The FDA pointed out that infants and critically ill patients face the highest risk, as they cannot speak up about symptoms. Nova Biomedical recorded one serious injury and zero deaths tied to the defect as of October 5, 2026.
What the announcement does not tell us
The FDA alert omits details about the single reported injury, including the patient's age and clinical outcome.
It does not state how many Gen 2.0 units are in use across American hospitals. Furthermore, the announcement does not give an exact release date in November 2026 for the software rollout, nor does it specify how long the phased deployment will take. Finally, the notice does not explain why older barcode data remains on the display screen in the first place.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.
Update use instructions for StatStrip Glucose Hospital Meter Systems due to the potential for glucose results to be assigned to the incorrect patient.
Opens www.fda.gov
More from FDA MedWatch Safety Alerts
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.